Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.56 |
| ▸ | HRH1 | P35367 | 3/20 | 0.56 |
| ▸ | DRD3 | P35462 | 3/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | HTR2A | P28223 | 3/20 | 0.56 |
| ▸ | HTR2B | P41595 | 3/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | APEX1 | P27695 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.56 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 4/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | HTR6 | P50406 | 3/20 | 0.52 |
| ▸ | HRH2 | P25021 | 6/20 | 0.46 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6776087 | 0.85 | LMNA (0.59) | LMNAHRH1DRD3KCNH2HTR2A | |
| SCHEMBL6782586 | 0.84 | HRH2 (0.59) | LMNAHRH1DRD3KCNH2HTR2A | |
| SCHEMBL6777203 | 0.83 | HTR2A (0.56) | LMNAHRH1DRD3KCNH2HTR2A | |
| SCHEMBL7159246 | 0.82 | DRD2 (0.49) | HTR2AHTR2BDRD2HTR6HRH2 | |
| SCHEMBL28747266 | 0.81 | DRD2 (0.49) | HTR2AHTR2BDRD2HTR6HRH2 | |
| SCHEMBL6777121 | 0.81 | DRD2 (0.62) | HTR2AHTR2BDRD2HTR6HRH2 | |
| SCHEMBL6780420 | 0.79 | DRD2 (0.59) | HTR2AHTR2BDRD2HTR6HRH2 | |
| SCHEMBL13285122 | 0.77 | LMNA (0.91) | LMNAHRH1DRD3KCNH2HTR2A | |
| SCHEMBL6782829 | 0.77 | HRH2 (0.46) | HTR2AHTR2BDRD2HTR6HRH2 | |
| SCHEMBL6775869 | 0.77 | HRH2 (0.62) | HTR2AHTR2BDRD2HTR6HRH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | claimed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | claimed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | claimed |
| EP-1183251-B1 | INDOLYLPIPERIDINE DERIVATIVES AS ANTIHISTAMINIC AND ANTIALLERGIC AGENTS | ALMIRALL PRODESFARMA SA (ES) | 2004-02-11 | — | — | EP | disclosed |
| US-6683096-B2 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2004-01-27 | — | — | US | disclosed |
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | ALMIRALL PRODESFARMA, S.A. (ES) | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147344-A1 | Indolylpiperidine derivatives as antihistaminic and antiallergic agents | HRH2, HRH1, HRH4 | LMNA 4761/4885HRH1 2/4885DRD3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.